Drugs Containing Excipient (Inactive Ingredient) ERYTHRITOL

Branded drugs containing ERYTHRITOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fortovia Therapeutics Inc	ZUPLENZ	ondansetron	89141-444	ERYTHRITOL

Generic drugs containing ERYTHRITOL excipient

Company	Ingredient	NDC	Excipient
Fortovia Therapeutics Inc	ondansetron	89141-444	ERYTHRITOL

Erythritol Pharmaceutical Excipient Market Dynamics, Patent Risk, and Financial Trajectory

Last updated: September 5, 2026

Erythritol is a fermentation-derived polyol used as a diluent, bulking agent, taste-masking aid, and low-calorie sweetener. Its pharmaceutical-excipient market is smaller and less transparent than its food and beverage market. Public manufacturers generally do not report erythritol revenue separately, so market estimates rely on third-party research and regional shipment data.

The commercial outlook is positive but divided. Food and beverage demand drives production scale, while pharmaceutical use depends on compendial quality, particle engineering, supply qualification, and formulation performance. China remains the main manufacturing base. Western suppliers compete through documentation, regulatory support, and specialty grades rather than commodity price alone.

Erythritol has no Orange Book listing, no drug-specific market exclusivity, and no biosimilar exposure. The relevant intellectual-property risks concern fermentation processes, purification, particle size, co-processing, pharmaceutical formulations, and branded delivery systems.

What is erythritol and how is it used as a pharmaceutical excipient?

Erythritol is a four-carbon sugar alcohol with the molecular formula C4H10O4. Commercial erythritol is generally produced by microbial fermentation of glucose or another carbohydrate substrate, followed by filtration, purification, crystallization, drying, and milling.

Its principal pharmaceutical functions are:

Function	Pharmaceutical relevance
Diluent and bulking agent	Adds mass to low-dose tablets, powders, sachets, and orally disintegrating formulations
Sweetness modifier	Masks bitterness in chewable tablets, oral powders, lozenges, and pediatric products
Cooling-mouthfeel agent	Provides an endothermic cooling sensation useful in oral products
Low-hygroscopicity carrier	Supports stability in some solid oral dosage forms
Co-processed excipient component	Can be combined with polymers, binders, or other sugars for direct compression
Nutritional substitute	Replaces sucrose in reduced-calorie formulations

Erythritol has about 60% to 70% of the sweetness of sucrose and contributes very few metabolizable calories. Its low gastrointestinal absorption and rapid urinary excretion distinguish it from sorbitol and maltitol, which are more likely to produce gastrointestinal effects at higher doses.

The ingredient is most relevant to oral solid dosage forms. It is less suitable where a formulation requires strong binding, high moisture retention, or extended-release functionality without modification.

What is the pharmaceutical excipient market size for erythritol?

No audited public market figure isolates pharmaceutical-grade erythritol from food, beverage, nutraceutical, and dental applications. Published market studies commonly combine these end uses and report materially different totals, depending on whether the analysis includes polyols, specialty sweeteners, or erythritol alone.

A practical market model is:

Market layer	Current commercial position
Total erythritol market	Dominated by food, beverage, nutraceutical, and tabletop sweetener use
Pharmaceutical-grade erythritol	Smaller niche with higher documentation and qualification requirements
Excipient-only demand	A subset of pharmaceutical and nutraceutical demand, not separately disclosed by most suppliers
Growth profile	Generally expected to exceed mature bulk-sweetener growth because of clean-label, reduced-sugar, and oral-dose applications
Revenue transparency	Low; supplier disclosures usually aggregate erythritol with sweeteners or specialty ingredients

Third-party estimates for the broader erythritol market typically imply multi-billion-dollar annual sales by the early 2030s, with mid-single-digit to high-single-digit compound annual growth rates. Those estimates should not be treated as pharmaceutical-excipient revenue. The pharmaceutical portion is likely a low-single-digit share of total volume but a higher share of gross margin because of testing, qualification, and documentation requirements.

The strongest demand indicators are:

1. Growth in orally disintegrating and chewable medicines.
2. Expansion of pediatric and geriatric dosage forms.
3. Increased use of sugar-free excipients in diabetes and weight-management products.
4. Demand for direct-compression and low-moisture excipient systems.
5. Wider use of pharmaceutical ingredients sourced through qualified Asian manufacturers.

Which companies manufacture or supply pharmaceutical-grade erythritol?

The supply chain is concentrated in China, with multinational ingredient companies participating through branded sweetener portfolios, distribution, technical service, or regional sourcing.

Company or supplier group	Market position
Baolingbao Biology Co., Ltd.	Chinese fermentation-based ingredient manufacturer with erythritol and related polyol capacity
Shandong Sanyuan Biotechnology Co., Ltd.	Large Chinese erythritol producer serving food, beverage, and industrial customers
Shandong Dongxiao Biotechnology Co., Ltd.	Chinese erythritol and sweetener producer
Cargill	Commercial participant through sweetener and reduced-calorie ingredient businesses, including erythritol-based offerings
Tate & Lyle	Ingredient supplier and formulation partner with sweetener systems and distribution capabilities
Ingredion	Specialty ingredient supplier with sweetener, bulking, and formulation support activities
Mitsubishi Chemical Group	Relevant to specialty chemicals and pharmaceutical excipient channels, although erythritol exposure is not generally reported separately

Chinese producers typically compete on fermentation scale and cost. Western suppliers compete on regulatory files, quality systems, supply consistency, regional warehousing, and formulation support.

A buyer qualifying erythritol for pharmaceutical use will normally evaluate:

• GMP status and manufacturing site history.
• Residual solvents and elemental impurities.
• Microbial limits and bioburden controls.
• Particle-size distribution.
• Bulk density and flow.
• Water content and hygroscopicity.
• Assay and related substances.
• Lot-to-lot consistency.
• Change-control procedures.
• DMF or equivalent technical documentation.
• Long-term supply and dual-sourcing capability.

What is the FDA regulatory status of erythritol?

Erythritol is permitted for use in food in the United States under FDA regulations and has a long history of use in food and oral-care products. FDA has also reviewed erythritol-related GRAS notices and ingredient submissions. Pharmaceutical use is governed primarily by product-specific formulation requirements and applicable excipient quality standards rather than by a standalone FDA approval for the excipient.

The regulatory position differs by jurisdiction:

Jurisdiction	Regulatory position
United States	Used in food and pharmaceutical products; excipient acceptance is assessed through the finished-product application
European Union	Authorized as a food additive under the E-number system; pharmaceutical use depends on product quality and regulatory documentation
Japan	Established use in food and pharmaceutical-related applications, subject to applicable standards
China	Major manufacturing jurisdiction with domestic and export supply
International	JECFA has evaluated erythritol and assigned an acceptable safety profile for food use

FDA does not grant a separate exclusivity period to an excipient supplier. A drug applicant may obtain regulatory protection for a finished product, but that protection does not prevent another company from manufacturing or selling erythritol as an excipient.

What patents protect erythritol manufacturing and pharmaceutical formulations?

Erythritol itself is an old, well-established compound. Composition-of-matter patent protection is not the principal commercial barrier. The relevant patent categories are process and application claims.

Fermentation and production patents

Process patents may claim:

• Genetically modified microorganisms.
• Fermentation media and carbon sources.
• pH, temperature, oxygen, and feed-control conditions.
• Continuous or fed-batch fermentation.
• Recovery of erythritol from fermentation broth.
• Crystallization and impurity-removal sequences.
• Yield improvement and reduction of by-products.
• Integrated production from starch hydrolysate.

These patents may matter to manufacturers operating at scale, but their risk depends on jurisdiction, filing date, prosecution history, claim scope, and whether the protected process is technically necessary.

Purification and particle-engineering patents

Other claims may cover:

• High-purity pharmaceutical-grade erythritol.
• Defined particle-size distributions.
• Granulated erythritol.
• Spray-dried or engineered particles.
• Low-dust grades.
• Improved flow and compressibility.
• Co-processing with binders or disintegrants.
• Formulations designed for rapid oral disintegration.

Particle-engineering patents are more relevant to pharmaceutical suppliers than broad erythritol patents because they can protect a commercial grade without controlling the entire molecule.

Method-of-use patents

Method-of-use claims may cover erythritol in:

• Sugar-free chewable tablets.
• Orally disintegrating tablets.
• Pediatric oral powders.
• Nutraceutical compositions.
• Dental-care formulations.
• Taste-masked active pharmaceutical ingredient systems.
• Low-calorie oral-care products.

These claims generally do not create a monopoly over erythritol supply. They may affect a particular finished product or formulation platform.

How strong is the patent estate for erythritol?

The core patent estate is moderate for manufacturing technology and potentially stronger for narrow formulation systems. It is weak as a basis for blocking generic access to erythritol itself.

Patent category	Relative risk	Commercial effect
Erythritol composition claims	Low	Compound is established and widely available
Basic fermentation process	Low to moderate	Older claims may have expired; newer process improvements may remain relevant
Engineered microorganisms	Moderate	Can create barriers for high-yield production
Purification and crystallization	Moderate	May affect cost and pharmaceutical-grade quality
Particle engineering	Moderate to high in narrow products	Can protect premium direct-compression or fast-disintegrating grades
Finished-dose formulation	Moderate	Risk depends on active ingredient, dosage form, and claim language
Manufacturing know-how	High practical importance	Trade secrets may matter even without enforceable patent claims

A complete freedom-to-operate review requires claim-level analysis by country. Patent databases contain many erythritol references, but a publication mentioning erythritol is not equivalent to an enforceable claim covering commercial production or pharmaceutical use.

When does erythritol lose exclusivity?

Erythritol has no single exclusivity-loss date because it is not a newly approved drug substance. The compound is broadly available from multiple manufacturers, and there is no Hatch-Waxman exclusivity period attached to the excipient.

The relevant timing questions are:

• When do process patents expire?
• When do formulation patents expire?
• Are continuation, divisional, or foreign counterparts still pending?
• Does a supplier rely on trade secrets rather than patents?
• Can a competitor produce an equivalent grade without practicing the claimed process?
• Does a finished drug product contain separate patents covering the active ingredient or dosage form?

U.S. utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and transitional rules. Foreign patents follow national laws and may produce different effective dates.

Are there Paragraph IV challenges for erythritol?

No conventional Paragraph IV market exists for erythritol as an excipient. Paragraph IV certifications apply to abbreviated new drug applications that challenge patents listed in the FDA Orange Book for a reference drug.

Erythritol may appear in an ANDA formulation, but the applicant would challenge patents covering the finished drug, not patents covering erythritol as a general excipient. Any litigation would therefore concern:

• The active pharmaceutical ingredient.
• The drug’s dosage form.
• A specific erythritol-containing formulation.
• A method of treatment.
• A listed drug-device combination.

There is no Orange Book exclusivity framework for standalone erythritol suppliers.

What is the Orange Book status of erythritol?

Erythritol has no standalone Orange Book listing. The FDA Orange Book lists approved drug products and patents submitted for those products. It does not function as a registry for general-purpose excipients.

Erythritol can still be present in an Orange Book-listed drug as an inactive ingredient. That presence does not give the erythritol manufacturer a patent right or exclusivity interest. Any listed patent belongs to the drug product sponsor and must cover the approved product or an applicable method of use.

What litigation and settlement risks affect erythritol?

Public litigation involving erythritol is more likely to concern food labeling, advertising, consumer safety, or finished-product formulations than pharmaceutical-excipient patent disputes.

For pharmaceutical buyers, the primary legal risks are:

1. Patent infringement claims against a specialized erythritol grade.
2. Trade-secret disputes involving fermentation strains or process controls.
3. Supplier qualification failures after a manufacturing change.
4. Product-liability or contamination claims.
5. Contract disputes involving specifications, exclusivity, or supply allocation.
6. Regulatory enforcement involving labeling or quality claims.

Settlement agreements are unlikely to create an industry-wide restriction because erythritol is available from multiple suppliers. A settlement could still restrict a particular manufacturer’s process, geographic sales, or supply to a named customer.

How does erythritol compare with mannitol, sorbitol, xylitol, and lactose?

Excipient	Main advantage	Main limitation	Typical pharmaceutical use
Erythritol	Sweet, cooling, low moisture absorption, low caloric contribution	Weaker binding and limited specialty-grade availability	Chewables, oral powders, ODTs
Mannitol	Excellent mouthfeel, low hygroscopicity, strong ODT history	Higher cost; can be brittle in some systems	ODTs, lyophilized products, tablets
Sorbitol	Strong sweetness and water solubility	Hygroscopicity and gastrointestinal tolerance concerns	Syrups, chewables, oral liquids
Xylitol	High sweetness and dental-care positioning	Cost and gastrointestinal tolerance at high intake	Chewables, lozenges, dental products
Lactose	Low cost, established compendial use, broad supply	Reducing sugar and lactose-intolerance considerations	Tablets, capsules, inhalation products

Mannitol is the closest pharmaceutical comparator for premium orally disintegrating formulations. Erythritol competes more effectively where sweetness, cooling sensation, and reduced-calorie positioning matter.

What is the financial trajectory for erythritol suppliers?

The financial trajectory is likely to be uneven across the value chain.

Near-term outlook

Commodity producers face price pressure when new Chinese capacity exceeds demand. Food and beverage volume growth can support utilization, but oversupply can compress margins. Pharmaceutical-grade material should retain a premium if suppliers maintain validated quality systems and consistent particle specifications.

Medium-term outlook

Revenue growth should come from:

• Sugar reduction in beverages and oral products.
• Expansion of sugar-free pharmaceuticals.
• Use in pediatric and geriatric formulations.
• Nutraceutical and sports-nutrition products.
• Premium direct-compression and co-processed grades.
• Regional supply diversification outside China.

Margin factors

Margin driver	Effect
Glucose or starch feedstock costs	Directly affects fermentation economics
Energy and drying costs	Material for crystallization and powder production
Plant utilization	Major determinant of commodity margins
Product purity	Supports pharmaceutical and premium pricing
Particle engineering	Increases value per kilogram
Regulatory documentation	Raises qualification value and switching costs
Freight and trade policy	Affects export competitiveness
Customer concentration	Increases contract and allocation risk

Public companies usually report erythritol within broader segments. Cargill, Tate & Lyle, Ingredion, and Chinese producers do not generally disclose a standalone pharmaceutical-erythritol profit line. Financial analysis should therefore focus on capacity, product mix, pricing, utilization, and customer qualification rather than reported erythritol revenue alone.

What generic entry risks exist for erythritol-containing drugs?

Generic entry risk is generally high for simple immediate-release products that use erythritol as a conventional inactive ingredient. The excipient itself is readily available and does not normally block substitution.

Risk increases when the product depends on:

• A narrow particle-size distribution.
• A proprietary co-processed excipient.
• A taste-masking system.
• A rapid-disintegration profile.
• A protected chewable formulation.
• A difficult active ingredient with poor compressibility.
• A device or packaging system tied to erythritol’s physical properties.
• A patent claiming specific excipient ratios or manufacturing steps.

In those cases, the commercial barrier comes from formulation replication and patent claims, not from erythritol supply scarcity.

What licensing deals affect erythritol?

Licensing activity is more common in branded sweetener systems, distribution, and formulation technology than in standalone pharmaceutical erythritol. Suppliers may enter:

• Regional distribution agreements.
• Private-label supply contracts.
• Co-development agreements for direct-compression grades.
• Technology licenses for fermentation strains.
• Long-term supply agreements with pharmaceutical manufacturers.
• Toll-manufacturing arrangements.

These contracts are usually confidential. A buyer should assume that supply continuity depends on commercial agreements, quality audits, and dual sourcing rather than on public patent licenses.

What geographic coverage matters for erythritol supply?

China is the principal production center and a major export source. North American and European customers face supply-chain exposure involving freight, customs, trade policy, currency, and quality audits.

Regional risk profile:

Region	Supply position	Main issue
China	Large production base	Price volatility, export dependence, qualification concentration
United States	Significant demand, less commodity production	Reliance on imported bulk material and specialty suppliers
European Union	Strong pharmaceutical manufacturing base	Regulatory documentation and supply diversification
Japan	Quality-sensitive specialty market	High qualification requirements
India	Growing pharmaceutical formulation base	Import dependence for some grades
Latin America	Primarily downstream demand	Exposure to freight and distributor inventory

Pharmaceutical customers increasingly favor two qualified sources, separate geographic inventory, and formal change-notification provisions.

Key Takeaways

• Erythritol is a high-volume fermentation product whose pharmaceutical-excipient market is a smaller, higher-value subset of total demand.
• Food, beverage, nutraceutical, and oral-care applications determine production scale and commodity pricing.
• Pharmaceutical growth is concentrated in chewables, orally disintegrating tablets, pediatric products, and low-sugar formulations.
• China is the dominant manufacturing base, while multinational suppliers compete through quality systems and formulation support.
• Erythritol has no standalone Orange Book listing, FDA drug exclusivity, or Paragraph IV challenge pathway.
• Patent risk centers on fermentation, purification, particle engineering, co-processing, and finished-dose formulations.
• The compound itself is unlikely to support durable exclusivity; specialized grades and manufacturing know-how can support stronger margins.
• Generic risk is high for simple formulations and higher for products protected by narrow excipient ratios, particle specifications, or taste-masking technology.
• Financial results should be assessed through capacity, utilization, pricing, quality premiums, and supply contracts because public companies rarely report erythritol revenue separately.

FAQs About Erythritol as a Pharmaceutical Excipient

Is erythritol listed in the FDA Inactive Ingredient Database?

Erythritol has been used in oral products, but database entries are dosage-form and route specific. A formulation sponsor must verify the applicable FDA Inactive Ingredient Database entry and permitted exposure for its proposed product.

Can erythritol be used in orally disintegrating tablets?

Yes. Its sweetness, cooling sensation, low hygroscopicity, and compressibility in engineered grades make it suitable for selected orally disintegrating tablets. Mannitol remains a major competing excipient.

Does erythritol require a Drug Master File?

A Drug Master File is not automatically required for every erythritol shipment. Pharmaceutical customers may request a DMF or equivalent quality package to support supplier qualification and regulatory filings.

Is pharmaceutical-grade erythritol materially more expensive than food-grade erythritol?

Usually, yes. The premium reflects tighter specifications, testing, documentation, audit requirements, controlled changes, and smaller production lots. The premium varies by particle size, packaging, certification, and region.

Can a pharmaceutical company switch erythritol suppliers without a regulatory filing?

The answer depends on the approved product, the scale of the change, and the applicable regulatory pathway. A supplier change may require comparability testing, stability data, quality documentation, and a regulatory submission if the change affects the product or its approved manufacturing process.

References

1. European Food Safety Authority. (2023). Re-evaluation of erythritol (E 968) as a food additive. EFSA Journal.

2. Food and Drug Administration. (n.d.). Inactive Ingredient Database. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. Joint FAO/WHO Expert Committee on Food Additives. (2018). Safety evaluation of certain food additives prepared by the eighty-sixth meeting of JECFA. World Health Organization.

5. U.S. Food and Drug Administration. (n.d.). GRAS notices inventory. U.S. Department of Health and Human Services.

6. Cargill, Incorporated. (2024). Annual report. Cargill.

7. Ingredion Incorporated. (2024). Annual report. Ingredion.

8. Tate & Lyle PLC. (2024). Annual report. Tate & Lyle.